Viridian Therapeutics Inc (NASDAQ: VRDN) on Monday, plunged -3.16% from the previous trading day, before settling in for the closing price of $17.41. Within the past 52 weeks, VRDN’s price has moved between $9.90 and $27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 31.28% over the past five years. The company achieved an average annual earnings per share of -7.33%. With a float of $73.61 million, this company’s outstanding shares have now reached $81.59 million.
Let’s look at the performance matrix of the company that is accounted for 143 employees. In terms of profitability, gross margin is -1858.28%, operating margin of -111591.06%, and the pretax margin is -102092.38%.
Viridian Therapeutics Inc (VRDN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viridian Therapeutics Inc is 9.78%, while institutional ownership is 103.68%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.97 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.32% during the next five years compared to 31.28% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Viridian Therapeutics Inc (VRDN) is currently performing well based on its current performance indicators. A quick ratio of 19.49 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4585.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.05, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -3.80 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics Inc (NASDAQ: VRDN) saw its 5-day average volume 0.69 million, a negative change from its year-to-date volume of 0.9 million. As of the previous 9 days, the stock’s Stochastic %D was 29.58%.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 78.20%, which indicates a significant increase from 18.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.79 in the past 14 days, which was lower than the 0.81 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.64, while its 200-day Moving Average is $17.12.
